Why the study?
Does orlistat and weight loss improve circulating levels of adiponectin, hs-CRP, and fibrinogen in obese subjects?
Population
93 obese subjects (mean weight: 108.9+/-15.8 kg)
Comparison
Orlistat combined with lifestyle intervention… vs Placebo combined with lifestyle intervention for…
Design
RCT, randomization to orlistat or placebo
Follow-up
3 years
Authors
Loading...
Orlistat aids weight maintenance without independent marker effects; extends RCT evidence that >10% loss is required to raise adiponectin in obesity.
Does orlistat and weight loss improve circulating levels of adiponectin, hs-CRP, and fibrinogen in obese subjects?
In obese subjects, a long-term weight loss exceeding 10% is required to induce significant improvements in inflammatory markers, with orlistat providing additional weight maintenance but no independent effect on these markers.
Madsen et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: